Floatz logo

Berzosertib

Small Cell Lung Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

276 Active assets in the Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
ANTI-PD-L1 MONOCLONAL ANTIBODY SHR-1316
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
ETOPOSIDE
Sichuan University
Phase 4BBB
Carboplatin
University of Maryland, Baltimore
Phase 4BB

View all 50 →

Same molecule, other indications

Berzosertib is also rated in:

small cell carcinomaActive
BB
Indicative · Phase 2
64 / 100
View asset →
fallopian tube carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
ovarian carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →